Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Glioma

ClinicalTrials.gov lists 3,318 trials for Glioma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 210.

MeSH D005910 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 953 Phase 1/2 Phase 1/2 377 Phase 2 Phase 2 858 Phase 2/3 Phase 2/3 27 Phase 3 Phase 3 149 Phase 4 Phase 4 14 Not applicable Not applicable 443 Observational Observational 468 Phase 1 Phase 1 953 Phase 1/2 Phase 1/2 377 Phase 2 Phase 2 858 Phase 2/3 Phase 2/3 27 Phase 3 Phase 3 149 Phase 4 Phase 4 14 Not applicable Not applicable 443 Observational Observational 468

Trials per phase (log scale)

1 more section with rows

1,443 of the 3,318 trials are tagged with Glioma itself; the rest are tagged with a narrower condition beneath it.

Get the Glioma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Glioma trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 20 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 189

1990: 1 trials (Phase 3 1) 1991: 2 trials (Phase 2 1, Phase 1 1) 1992: 2 trials (Observational 1, Phase 2 1) 1993: 3 trials (Phase 2 1, Phase 1/2 1, Phase 1 1) 1994: 11 trials (Observational 1, Phase 3 3, Phase 2 4, Phase 1 3) 1995: 9 trials (Observational 2, Phase 2 4, Phase 1/2 1, Phase 1 2) 1996: 18 trials (Not applicable 1, Phase 3 1, Phase 2 12, Phase 1 4) 1997: 20 trials (Observational 1, Phase 3 2, Phase 2 10, Phase 1/2 1, Phase 1 6) 1998: 33 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 14, Phase 1/2 4, Phase 1 10) 1999: 33 trials (Observational 2, Phase 3 2, Phase 2 16, Phase 1/2 2, Phase 1 11) 2000: 40 trials (Phase 3 2, Phase 2 16, Phase 1/2 13, Phase 1 9) 2001: 42 trials (Observational 2, Not applicable 1, Phase 3 3, Phase 2 16, Phase 1/2 8, Phase 1 12) 2002: 55 trials (Observational 2, Phase 3 3, Phase 2 18, Phase 1/2 11, Phase 1 21) 2003: 38 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 2 20, Phase 1/2 2, Phase 1 8) 2004: 57 trials (Observational 11, Not applicable 4, Phase 3 9, Phase 2 13, Phase 1/2 6, Phase 1 14) 2005: 84 trials (Observational 7, Not applicable 5, Phase 3 6, Phase 2 27, Phase 1/2 9, Phase 1 30) 2006: 84 trials (Observational 12, Not applicable 5, Phase 3 6, Phase 2/3 1, Phase 2 32, Phase 1/2 10, Phase 1 18) 2007: 87 trials (Observational 6, Not applicable 2, Phase 3 7, Phase 2/3 1, Phase 2 41, Phase 1/2 8, Phase 1 22) 2008: 84 trials (Observational 11, Not applicable 5, Phase 4 1, Phase 3 8, Phase 2 32, Phase 1/2 7, Phase 1 20) 2009: 117 trials (Observational 11, Not applicable 7, Phase 3 8, Phase 2 39, Phase 1/2 16, Phase 1 36) 2010: 115 trials (Observational 9, Not applicable 7, Phase 3 6, Phase 2 40, Phase 1/2 16, Phase 1 37) 2011: 108 trials (Observational 10, Not applicable 9, Phase 3 5, Phase 2/3 2, Phase 2 35, Phase 1/2 16, Phase 1 31) 2012: 94 trials (Observational 11, Not applicable 13, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 22, Phase 1/2 13, Phase 1 29) 2013: 102 trials (Observational 9, Not applicable 18, Phase 3 4, Phase 2 28, Phase 1/2 12, Phase 1 31) 2014: 122 trials (Observational 19, Not applicable 18, Phase 3 3, Phase 2/3 3, Phase 2 29, Phase 1/2 10, Phase 1 40) 2015: 123 trials (Observational 19, Not applicable 18, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 28, Phase 1/2 15, Phase 1 36) 2016: 138 trials (Observational 28, Not applicable 13, Phase 3 3, Phase 2/3 2, Phase 2 29, Phase 1/2 20, Phase 1 43) 2017: 147 trials (Observational 25, Not applicable 24, Phase 3 3, Phase 2/3 1, Phase 2 45, Phase 1/2 14, Phase 1 35) 2018: 165 trials (Observational 30, Not applicable 26, Phase 4 2, Phase 3 6, Phase 2/3 4, Phase 2 25, Phase 1/2 19, Phase 1 53) 2019: 136 trials (Observational 21, Not applicable 21, Phase 4 2, Phase 3 2, Phase 2/3 2, Phase 2 35, Phase 1/2 14, Phase 1 39) 2020: 150 trials (Observational 19, Not applicable 28, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 2 36, Phase 1/2 17, Phase 1 43) 2021: 142 trials (Observational 25, Not applicable 28, Phase 3 3, Phase 2 26, Phase 1/2 18, Phase 1 42) 2022: 189 trials (Observational 38, Not applicable 39, Phase 4 2, Phase 3 6, Phase 2 30, Phase 1/2 20, Phase 1 54) 2023: 165 trials (Observational 38, Not applicable 32, Phase 3 4, Phase 2/3 1, Phase 2 21, Phase 1/2 16, Phase 1 53) 2024: 175 trials (Observational 40, Not applicable 35, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 36, Phase 1/2 14, Phase 1 41) 2025: 170 trials (Observational 27, Not applicable 37, Phase 4 1, Phase 3 9, Phase 2/3 1, Phase 2 27, Phase 1/2 14, Phase 1 54)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 190
2025 170
2024 175
2023 165
2022 189
2021 142
2020 150
2019 136
2018 165
2017 147

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 210 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 461 trials still running at the 2026-10-09 snapshot; registered median of 42 months across 1,884 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Glioma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 953
Phase 1/2 377
Phase 2 858
Phase 2/3 27
Phase 3 149
Phase 4 14
Not applicable 443
Observational 468
Expanded access 29

How many Glioma trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 156
Recruiting 533
Enrolling by invitation 13
Active, not recruiting 250
Available 8

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Glioma trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 210
Children's Oncology Group 36
Novartis Pharmaceuticals 30
European Organisation for Research and Treatment of Cancer - EORTC 28
Pediatric Brain Tumor Consortium 26

Which drugs are being tested for Glioma? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 56
Irinotecan 52
NIVOLUMAB 45
PEMBROLIZUMAB 44

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 454
Radiation Therapy 182
Bevacizumab 1 155
Lomustine Pill 66
or carboplatin 62

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Glioma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Seizure 1,091 245
Platelet count decreased 503 74
Headache 455 175
Fatigue 407 125
Vomiting 381 159

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Glioma? (1,080)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial. The Lancet. Oncology 2026 Yes
Infant-Type Hemispheric Gliomas: A Review of Clinical, Radiologic, Histopathologic, and Molecular Features. Journal of the National Comprehensive Cancer Network : JNCCN 2025 Yes
Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME). Cancer medicine 2025 Yes
Rapid diagnosis of adult-type diffuse glioma using a layered scheme. BMC medicine 2025 Yes
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial. Nature medicine 2025 Yes

Showing 5 of 1,080 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (15)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Glial tumor Annual incidence 1-9 / 100 000 United States US Unspecified
Glial tumor Annual incidence 1-9 / 100 000 United States US Exact
Glial tumor Annual incidence 1-9 / 100 000 United States US Exact
Glial tumor Annual incidence 1-9 / 100 000 Croatia Not stated Exact
Glial tumor Annual incidence 1-9 / 100 000 Croatia Not stated Unspecified

Showing 5 of 15 prevalence observations.

Start your 14-day trial Email me all 15 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Glial tumor 182067 Exact Orphadata Science knowledge files, Product 1
Glial tumor 182067 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages